Skip to main content

Diverticulitis

2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Dr. Falk Pharma
Dr. Falk PharmaGermany - Freiburg
2 programs
2
MesalazinePhase 31 trial
MesalazinePhase 31 trial
Active Trials
NCT01038739Terminated330Est. Jan 2013
NCT00695643Terminated345Est. Jan 2012
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
Colon resectionN/A
Early Post-Op Recovery After Partial Large Bowel ResectionN/A1 trial
Active Trials
NCT00492193Completed139Est. May 2008
MSD
MSDIreland - Ballydine
1 program
Colon resectionN/A1 trial
Active Trials
NCT01986686Completed107Est. Jul 2016
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Colon resectionN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dr. Falk PharmaMesalazine
Dr. Falk PharmaMesalazine
MSDColon resection
Merck & Co.Early Post-Op Recovery After Partial Large Bowel Resection

Clinical Trials (4)

Total enrollment: 921 patients across 4 trials

NCT01038739Dr. Falk PharmaMesalazine

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

Start: Jan 2010Est. completion: Jan 2013330 patients
Phase 3Terminated
NCT00695643Dr. Falk PharmaMesalazine

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

Start: Jan 2008Est. completion: Jan 2012345 patients
Phase 3Terminated
NCT01986686MSDColon resection

Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis

Start: Oct 2011Est. completion: Jul 2016107 patients
N/ACompleted
NCT00492193Merck & Co.Early Post-Op Recovery After Partial Large Bowel Resection

Early Post-Op Recovery After Partial Large Bowel Resection

Start: Jun 2007Est. completion: May 2008139 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.